Papillary thyroid cancer organoids harboring BRAF^V600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies.

ABSTRACT:

Backgrounds

Papillary thyroid cancer (PTC), which is often driven by acquired somatic mutations in BRAF genes, is the most common pathologic type of thyroid cancer. PTC has an excellent prognosis after treatment with conventional therapies such as surgical resection, thyroid hormone therapy and adjuvant radioactive iodine therapy. Unfortunately, about 20% of patients develop regional recurrence or distant metastasis, making targeted therapeutics an important treatment option. Current in vitro PTC models are limited in representing the cellular and mutational characteristics of parental tumors. A clinically relevant tool that predicts the efficacy of therapy for individuals is urgently needed.

Methods

Surgically removed PTC tissue samples were dissociated, plated into Matrige

SUBMITTER: Chen D 

PROVIDER: S-EPMC9827684 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature